Author

Z. A. Bornholdt

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:host-pathogen & immune response· 3 Organism:non-human primate· 3 Research Focus:drug response / drug discovery· 2 Organism:human· 1 Organism:mouse· 1 Assay:proteomics· 1 Organism:virus· 1

Frequent Co-Authors

A. Z. Wec· 3 shared C. L. Moyer· 3 shared D. M. Abelson· 3 shared J. B. Geisbert· 3 shared K. Chandran· 3 shared K. N. Agans· 3 shared L. M. Walker· 3 shared L. Zeitlin· 3 shared

Activity by Year

2018-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

A. Z. Wec

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Reversion of Ebolavirus Disease from a Single Intramuscular Injection of a pan-Ebolavirus Immunotherapeutic

E. Kuang, R. W. Cross, M. McCavitt-Malvido, D. M. Abelson, V. Borisevich, K. N. Agans, N. Mlakar, A. Marimuthu, D. J. Deer, W. S. Shestowsky, D. Kim, J. B. Geisbert, L. Zeitlin, C. L. Moyer, C. J. Roy, , Z. A. Bornholdt

This study shows that a single intramuscular dose of MBP431, a modified ebolavirus therapeutic, can reverse disease and provide protection in non-human primates.

bioRxiv · Jan 6, 2022Microbiology

Genotype-specific Features Reduce the Susceptibility of South American Yellow Fever Virus Strains to Vaccine-Induced Antibodies

D. Haslwanter, G. Lasso, A. Z. Wec, N. D. Furtado, L. M. S. Raphael, Y. Sun, S. Stransky, N. Pedreno-Lopez, A. Tse, C. A. Correia, Z. A. Bornholdt, M. Sakharkar, V. I. Avelino-Silva, C. L. Moyer, D. I. Watkins, , K. Chandran

This study shows that South American yellow fever virus strains are less susceptible to vaccine-induced antibodies due to genetic changes in the glycoprotein E.

bioRxiv · Aug 22, 2021Microbiology

Prior vaccination with the rVSV-ZEBOV vaccine does not interfere with but improves the efficacy of postexposure antibody treatment in nonhuman primates exposed to Ebola virus

R. W. Cross, Z. A. Bornholdt, A. N. Prasad, J. B. Geisbert, V. Borisevich, K. N. Agans, D. J. Deer, K. Melody, K. A. Fenton, H. Feldmann, A. Sprecher, T. W. Geisbert

bioRxiv · Apr 1, 2020Microbiology

Human antibody cocktail deploys multiple functions to confer pan-ebolavirus protection

A. Z. Wec, Z. A. Bornholdt, S. He, A. S. Herbert, E. Goodwin, A. S. Wirchnianski, B. M. Gunn, Z. Zhang, W. Zhu, G. Liu, D. M. Abelson, C. L. Moyer, R. K. Jangra, R. M. James, R. R. Bakken, , K. Chandran

This paper develops a human antibody cocktail, MBP134, that provides broad protection against multiple ebolaviruses, showing enhanced efficacy in guinea pigs compared to individual antibodies.

bioRxiv · Aug 20, 2018Microbiology

Two-antibody pan-ebolavirus cocktail confers broad therapeutic protection in ferrets and nonhuman primates

Z. A. Bornholdt, A. S. Herbert, C. E. Mire, S. He, R. W. Cross, A. Z. Wec, D. M. Abelson, J. B. Geisbert, R. M. James, M. N. Rahim, W. Zhu, V. Borisevich, L. Banadyga, B. M. Gunn, K. N. Agans, , J. M. Dye

This paper demonstrates that a two-antibody cocktail (MBP134AF) provides broad therapeutic protection against multiple ebolaviruses in ferrets and nonhuman primates.

bioRxiv · Aug 19, 2018Microbiology